Acute Ischemic Stroke - Pipeline Insight, 2024

This “Acute Ischemic Stroke- Pipeline Insight, 2024” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Ischemic Stroke: Understanding

Acute Ischemic Stroke: Overview

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. Acute ischemic stroke is a leading cause of death and disability in the US and affects approximately 7, 00,000 people each year. This condition occurs when blood vessels that supply the brain are either blocked by a clot or become too narrow for blood to pass through. This lack of blood flow prevents oxygen and nutrients from reaching brain tissue, causing the affected brain cells to die within minutes to hours. The severity and the symptoms of an ischemic stroke depend on the area of the brain affected and the amount of tissue damaged.

Signs and symptoms of stroke may include sudden-onset numbness or weakness in an arm or leg, facial droop, difficulty speaking or understanding speech, confusion, trouble with balance or coordination, and loss of vision. Symptoms of an acute ischemic stroke can vary but often include sudden numbness or weakness, especially on one side of the body, confusion, trouble speaking or understanding speech, visual disturbances, severe headache with no known cause. The specific symptoms experienced by a person can help healthcare providers determine the area of the brain that is affected. Because stroke symptoms signify a true emergency, immediate medical attention is crucial to minimize brain damage and potential complications. Acute ischemic stroke is sometimes preceded by a transient ischemic attack (TIA), which is a temporary episode of brain dysfunction due to decreased blood flow. The primary risk factor for acute ischemic stroke is high blood pressure. Other conditions associated with an increased risk of stroke include history of TIAs, cigarette smoking, high cholesterol, diabetes, obesity, end-stage kidney disease, and a heart rhythm disorder called atrial fibrillation.

Diagnosis of an acute ischemic stroke involves a combination of medical history, physical examination, and diagnostic tests. Imaging tests such as computed tomography (CT) scans and magnetic resonance imaging (MRI) are critical for determining the type of stroke and the affected brain areas. Treatment focuses on restoring blood flow to the brain as quickly as possible. This may involve the use of clot-busting drugs (thrombolytics), mechanical clot removal in certain cases, and medications to prevent further clots and reduce stroke risk. Rehabilitation, including physical, occupational, and speech therapy, may be necessary to help individuals regain strength, mobility, and speech functions affected by the stroke. The goal of therapy in acute ischemic stroke is to preserve tissue in areas where perfusion is decreased but sufficient to avoid infarction. Tissue in this area of oligemia is preserved by restoring blood flow to the compromised regions and improving collateral flow. Recanalization strategies include recombinant tissue-type plasminogen activator. Restoring blood flow can minimize the effects of ischemia only if performed quickly. The promptness of treatment significantly influences recovery outcomes, making it essential to seek immediate care for anyone showing signs of stroke.

“Acute Ischemic Stroke- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Ischemic Stroke pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke treatment guidelines. The assessment part of the report embraces, in depth Acute Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Ischemic Stroke R&D. The therapies under development are focused on novel approaches to treat/improve Acute Ischemic Stroke.

Acute Ischemic Stroke Emerging Drugs Chapters

This segment of the Acute Ischemic Stroke report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Ischemic Stroke Emerging Drugs

• Nelonemdaz: GNT Pharma

Nelonemdaz is a moderate NR2B-selective N-methyl d-aspartate (NMDA) receptor antagonist and potent spin trapper that reduces NMDA receptor-mediated excitotoxicity and oxidative stress, two major routes of brain cell death leading to disability and death after stroke. Nelonemdaz previously showed better efficacy and a longer therapeutic time window than subtype-unselective NMDA antagonists or antioxidants alone in 5 animal models of stroke. Its safety and tolerability in humans has been established in two earlier phase I studies conducted in 165 healthy young and elderly volunteers in the US and China. Currently, the drug is in Phase III stage of its development for the treatment of acute ischemic stroke.

• Glenzocimab : Acticor Biotech

Glenzocimab (ACT017), a humanized monoclonal antibody (mAb) fragment directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain. In May 2022, Acticor Biotech presented positive results from its Phase 1b/2a study, ACTIMIS, at the ESOC, confirming the safety profile and showing a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke. Acticor Biotech announced the issuance of a patent in Europe for glenzocimab, for the treatment of cardiovascular emergencies glenzocimab-treated group in patients with stroke. Currently, the drug is in Phase II/III stage of its development for the treatment of acute ischemic stroke.

• NoNO-42: NoNO Inc.

NoNO-42 is the next generation drug developed in NoNO’s PSD-95 inhibitor platform. It is intended for the treatment of all people experiencing an acute ischemic stroke. NoNO-42 for the StrokePen program is presently in Phase 1 for use in people experiencing an acute ischemic stroke with or without thrombolytics. NoNO-42 was developed to be administered with or without thrombolytic agents. It extends the potential benefits of PSD-95 inhibition to those patients who, in ESCAPE-NA1 were previously treated with thrombolytics and therefore could not benefit from nerinetide. Currently, the drug is in Phase I stage of its development for the treatment of acute ischemic stroke.

Acute Ischemic Stroke: Therapeutic Assessment

This segment of the report provides insights about the different Acute Ischemic Stroke drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Ischemic Stroke

• There are approx. 30+ key companies which are developing the therapies for Acute Ischemic Stroke. The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include, GNT Pharma.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Ischemic Stroke: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Ischemic Stroke therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Ischemic Stroke drugs.

Acute Ischemic Stroke Report Insights

• Acute Ischemic Stroke Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Ischemic Stroke Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Ischemic Stroke drugs?
• How many Acute Ischemic Stroke drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Ischemic Stroke?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Ischemic Stroke therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Ischemic Stroke and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GNT Pharma
• Acticor Biotech
• NoNO Inc.
• Shijiazhuang Yiling Pharmaceutical Co. Ltd
• Ever Supreme Bio Technology Co., Ltd
• Meridigen Biotech Co., Ltd.
• Kunming Pharmaceuticals, Inc.
• Shin Poong Pharmaceutical Co. Ltd.
• Jiangsu Simcere Pharmaceutical Co., Ltd.
• Tasly Biopharmaceuticals Co., Ltd.
• Shionogi
• DiaMedica Therapeutics Inc
• Prolong Pharmaceuticals
• Silver Creek Pharmaceuticals
• NoNO Inc
• NeuroTrauma Sciences, LLC

Key Products

• Nelonemdaz
• Glenzocimab
• NoNO-42
• XY03-EA
• UMSC01
• UMC119-06
• KPCXM18
• SP-8203
• SIM1910-09
• Prourokinase recombinant
• Redasemtide
• DM199
• PP-007
• scp776
• Nerinetide
• NTS-104

This product will be delivered within 1-3 business days.